$MIRM SEC Filings

Announcement of Positive Results from Cohort 2 of the Pivotal PROGRESS Study of ATEBRIOZ™ (zilurgisertib) in Pediatric Patients Aged 6 to <12 Years with Fibrodysplasia Ossificans Progressiva

Received 16,112 shares by exercise or conversion ($310K)

Granted 40,000 Employee Stock Option (right to buy) · Granted 25,000 Restricted Stock Units

On October 12, 2026, Mirum Pharmaceuticals, Inc. (the “Company”) announced topline results from the Phase 3 EXPAND study evaluating LIVMARLI (maralixibat) (“Livmarli”) for the treatment of cholestatic pruritus in patients aged 6 months o...

Received 12,197 shares by exercise or conversion ($211K)

On September 25, 2026, Mirum Pharmaceuticals, Inc. (the “Company”) and Incyte Corporation (“Incyte”) announced that the U.S. Food and Drug Administration (“FDA”) approved Atebrioz™ (zilurgisertib) tablets to reduce the volume of total ne...

Holds 55 shares of Common Stock

Received 18,333 shares by exercise or conversion · Sold 9,943 shares ($978K)

On September 8, 2026, Mirum Pharmaceuticals, Inc. (the “Company”) announced that, on September 2, 2026, the Company’s Board of Directors appointed Rob Myers, M.D., to succeed Joanne Quan, M.D., as the Company’s Chief Medical Officer, eff...

Sold 658 shares ($65.8K)

Received 30,000 shares by exercise or conversion ($88.1K) · Sold 30,000 shares ($2.96M)

Received 40,000 shares by exercise or conversion ($251K) · Sold 40,000 shares ($4M)

Sold 6,001 shares ($600K)

Received 20,000 shares by exercise or conversion ($58.7K) · Sold 20,000 shares ($1.98M)